TAS::75 0849::TAS THE CONTRACTOR WILL DEVELOP A PROPRIETARY YEAST PRODUCTION PL

Biosavita, Inc., Plymouth MI

Investigators

Abstract

ApoLife is developing yeast platform-Twin Cassette yeast vectors for cost effective manufacturing of antibodies. Using recent collaboration with a company with proprietary S. cerevisiae yeast strains producing homogeneous human N-linked glycosylated proteins, ApoLife will develop commercial scale process for cost effective manufacturing of Campth, anticancer antibody, as a biogeneric antibody candidate. ApoLife has expressed Campath genes in yeast system.